Interview: Xu Hang – CEO, Mindray, China
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
Address: Mindray Building, Keji 12th Road South, High-tech Industrial Park, Nanshan, Shenzhen 518057, P. R. China.,China
Tel: +86 (755) 26582888
Web: http://www.mindray.com/main/index.jsp
Mindray was founded in 1991 in Shenzhen, China, with a mission to deliver high-quality, competitively priced medical devices to make healthcare more accessible and affordable around the world. Over the last 18 years, Mindray has become a leading developer, manufacturer and marketer of medical devices worldwide. According to Frost & Sullivan, in 2006 Mindray attained a leading market share in China both by units sold and revenue for the sale of patient monitoring devices. Mindray also holds a leading market share in China in the three-part differentiation hematology analyzer, biochemistry analyzer and black and white ultrasound imaging system segments.
Our success has been deeply rooted in our commitment to invest approximately 10% of our revenues into R&D every year. With more than 1,530 engineers on staff, Mindray has built a world-class platform that capitalizes on low-cost China based R&D operations and a culture that is driven by ingenuity, and both individual and team performance. Mindray currently offers more than 40 products across three business segments including patient monitoring devices and life support products, in-vitro diagnostic instruments and medical imaging systems. Mindray expects to continue to introduce six to eight new products each year to broaden market reach. Mindray is confident that our growing comprehensive portfolio of high-quality, affordable products will allow the company to continue gaining market share both domestically and internationally.
In China, Mindray has distributed products to over 40,000 hospitals, clinics, and healthcare facilities. Outside China, Mindray has sold devices in over 190 countries. Mindray began exporting our products for the first time in 2000; and in the second half of 2007, revenues generated from international markets exceeded domestic revenues for the first time in Mindray’s operating history.
By June 2009, Mindray had a total of approximately 5,600 employees worldwide, and Mindray is expanding its distribution, sales and service network to bring products closer to end users. Mindray currently has 29 branch companies in major cities of China, as well as 12 overseas subsidiaries in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Milan, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver.
Mindray’s American Depositary Shares (ADSs) are listed on the New York Stock Exchange (NYSE) under the symbol MR.
patient monitoring, diagnostics and ultrasound imaging systems
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
You have had significant experience at GSK and Pfizer, and also at Frontage Labs doing more entrepreneurial work. What ultimately brought you to Covance? I worked in Big Pharma for…
Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations, making it more convenient…
Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you…
Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine that breaking into this…
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Liam Condon, Managing Director of Bayer Healthcare China discusses the government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s…
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely…
See our Cookie Privacy Policy Here